Next Article in Journal
Pneumococcal Carriage in Infants Post-PCV10 Introduction in Pakistan: Results from Serial Cross-Sectional Surveys
Next Article in Special Issue
Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
Previous Article in Journal
Opposing Role of Trust as a Modifier of COVID-19 Vaccine Uptake in an Indigenous Population
Previous Article in Special Issue
Antibody- and T Cell-Dependent Responses Elicited by a SARS-CoV-2 Adenoviral-Based Vaccine in a Socially Vulnerable Cohort of Elderly Individuals
vaccines-logo
Article Menu

Article Menu

Article

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021

1
Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
2
Indian Council of Medical Research—National Institute of Virology, Pune 411001, India
3
Greater Chennai Corporation, Ripon Building, Chennai 600003, India
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Francesco Paolo Bianchi and Silvio Tafuri
Vaccines 2022, 10(6), 970; https://doi.org/10.3390/vaccines10060970
Received: 2 May 2022 / Revised: 6 June 2022 / Accepted: 14 June 2022 / Published: 17 June 2022
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection. View Full-Text
Keywords: COVID-19 vaccines; vaccine effectiveness; ChAdOx1 nCoV-19; Covishield; AZD 1222; SARS-CoV-2 inactivated vaccines COVID-19 vaccines; vaccine effectiveness; ChAdOx1 nCoV-19; Covishield; AZD 1222; SARS-CoV-2 inactivated vaccines
Show Figures

Figure 1

MDPI and ACS Style

Murali, S.; Sakthivel, M.; Pattabi, K.; Venkatasamy, V.; Thangaraj, J.W.V.; Shete, A.; Varghese, A.J.; Arjun, J.; Kumar, C.P.G.; Yadav, P.D.; Sahay, R.; Majumdar, T.; Dudhmal, M.; Sivalingam, A.; Dhanapal, S.R.; Durai Samy, A.; Radhakrishnan, V.; Muni Krishnaiah, M.M.; Arunachalam, S.; Gandhi, P.M.K.; Govindasamy, E.; Chinnappan, P.; Sekar, D.P.V.; Marappan, P.; Pounraj, E.; Ganeshkumar, P.; Jagadeesan, M.; Narnaware, M.; Bedi, G.S.; Kaur, P.; Murhekar, M. Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. Vaccines 2022, 10, 970. https://doi.org/10.3390/vaccines10060970

AMA Style

Murali S, Sakthivel M, Pattabi K, Venkatasamy V, Thangaraj JWV, Shete A, Varghese AJ, Arjun J, Kumar CPG, Yadav PD, Sahay R, Majumdar T, Dudhmal M, Sivalingam A, Dhanapal SR, Durai Samy A, Radhakrishnan V, Muni Krishnaiah MM, Arunachalam S, Gandhi PMK, Govindasamy E, Chinnappan P, Sekar DPV, Marappan P, Pounraj E, Ganeshkumar P, Jagadeesan M, Narnaware M, Bedi GS, Kaur P, Murhekar M. Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. Vaccines. 2022; 10(6):970. https://doi.org/10.3390/vaccines10060970

Chicago/Turabian Style

Murali, Sharan, Manikandanesan Sakthivel, Kamaraj Pattabi, Vettrichelvan Venkatasamy, Jeromie W.V. Thangaraj, Anita Shete, Alby J. Varghese, Jaganathan Arjun, Chethrapilly P.G. Kumar, Pragya D. Yadav, Rima Sahay, Triparna Majumdar, Manisha Dudhmal, Azhagendran Sivalingam, Sudha R. Dhanapal, Augustine Durai Samy, Vijayaprabha Radhakrishnan, Murali M. Muni Krishnaiah, Suresh Arunachalam, Punita M.K. Gandhi, Elavarasu Govindasamy, Prabhakaran Chinnappan, Dhana P.V. Sekar, Prakash Marappan, Ezhil Pounraj, Parasuraman Ganeshkumar, Murugesan Jagadeesan, Manish Narnaware, Gagandeep S. Bedi, Prabhdeep Kaur, and Manoj Murhekar. 2022. "Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021" Vaccines 10, no. 6: 970. https://doi.org/10.3390/vaccines10060970

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop